{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:43:20Z","timestamp":1787579000182,"version":"build-2736575974"},"reference-count":46,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AstraZeneca Canada"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Patients with hematological malignancies have an increased risk of serious outcomes following COVID-19 infection, suggesting broader protection is needed beyond vaccination. Monoclonal antibodies such as sotrovimab, casirivimab\u2013imdevimab, and bamlanivimab have provided valuable options for the treatment of COVID-19 disease. More recently, monoclonal antibodies have been examined for the prevention of COVID-19 infection. The monoclonal antibody combination, tixagevimab\u2013cilgavimab, was recently approved by Health Canada as pre-exposure prophylaxis against COVID-19 in individuals who are immunocompromised or where vaccination is not recommended. Prophylactic approaches such as the use of tixagevimab\u2013cilgavimab, in addition to COVID-19 vaccination, may provide additional protection for patients with hematological malignancies who are at greater risk of serious outcomes from COVID-19 infection.<\/jats:p>","DOI":"10.3390\/curroncol29060315","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T05:25:42Z","timestamp":1653974742000},"page":"3940-3949","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies"],"prefix":"10.3390","volume":"29","author":[{"given":"Carolyn","family":"Owen","sequence":"first","affiliation":[{"name":"Division of Hematology and Hematological Malignancies, University of Calgary and Foothills Medical Centre, Calgary, AB T2N 4Z6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Robinson","sequence":"additional","affiliation":[{"name":"Division of Hematology, Dalhousie University, Halifax, NS B3H 4R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6421-8728","authenticated-orcid":false,"given":"Anna","family":"Christofides","sequence":"additional","affiliation":[{"name":"IMPACT Medicom Inc., Toronto, ON M6S 3K2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1860-9765","authenticated-orcid":false,"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"BC Cancer Centre for Lymphoid Cancer, and The University of British Columbia, Vancouver, BC V6T 1Z4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"ref_1","unstructured":"(2022, March 02). COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Available online: https:\/\/github.com\/CSSEGISandData\/COVID-19."},{"key":"ref_2","unstructured":"(2022, March 03). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.15585\/mmwr.mm7044e3","article-title":"Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19\u2013Associated Hospitalizations Among Immunocompromised Adults\u2014Nine States","volume":"70","author":"Embi","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_5","unstructured":"Statistics Canada (2020). Health Reports: Health-Related Concerns and Precautions during the COVID-19 Pandemic: A Comparison of Canadians with and without Underlying Health Conditions, Statistics Canada."},{"key":"ref_6","unstructured":"(2022, March 03). Fact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld\u2122 (Tixagevimab Co-Packaged with Cilgavimab), Available online: https:\/\/www.fda.gov\/media\/154701\/download."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.7326\/M21-1757","article-title":"Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study","volume":"174","author":"Deepak","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/cid\/ciab687","article-title":"Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing COVID-19 Hospitalizations in the United States","volume":"74","author":"Tenforde","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jinf.2021.12.044","article-title":"Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups","volume":"84","author":"Whitaker","year":"2022","journal-title":"J. Infect."},{"key":"ref_10","first-page":"n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study","volume":"373","author":"Andrews","year":"2021","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","article-title":"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study","volume":"397","author":"Hall","year":"2021","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","first-page":"100134","article-title":"Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study","volume":"6","author":"Bruxvoort","year":"2022","journal-title":"Lancet Reg. Health Am."},{"key":"ref_14","unstructured":"(2022, March 28). Antibody Testing Is Not Currently Recommended to Assess Immunity after COVID-19 Vaccination: FDA Safety Communication, Available online: https:\/\/www.fda.gov\/medical-devices\/safety-communications\/antibody-testing-not-currently-recommended-assess-immunity-after-covid-19-vaccination-fda-safety."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e069761","DOI":"10.1136\/bmj-2021-069761","article-title":"Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study","volume":"376","author":"Lauring","year":"2022","journal-title":"BMJ"},{"key":"ref_16","unstructured":"(2022, April 14). An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Available online: https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/immunization\/national-advisory-committee-on-immunization-naci\/naci-guidance-second-booster-dose-covid-19-vaccines.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2021014085","article-title":"Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination","volume":"139","author":"Herishanu","year":"2022","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","article-title":"Protection by a Fourth Dose of BNT162b2 against Omicron in Israel","volume":"386","author":"Goldberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: An observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hon.2957","article-title":"SARS-CoV-2 vaccine response in CAR T-cell therapy recipients: A systematic review and preliminary observations","volume":"40","author":"Abid","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Gutwein","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s43018-021-00275-9","article-title":"Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: The CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chang, A., Akhtar, A., Linderman, S.L., Lai, L., Orellana-Noia, V.M., Valanparambil, R., Ahmed, H., Zarnitsyna, V.I., McCook-Veal, A.A., and Switchenko, J.M. (2022). Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. J. Clin. Oncol., JCO2200088.","DOI":"10.1200\/JCO.22.00088"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/blood.2021013768","article-title":"Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting","volume":"139","author":"Mittelman","year":"2022","journal-title":"Blood"},{"key":"ref_28","first-page":"2418","article-title":"Characteristics and Outcomes of COVID-19 Patients with Mature B-Cell Non-Hodgkin Lymphomas (mB-Cell NHL): A US Nationwide Electronic Health Record (EHR) Database Study","volume":"138","author":"Yue","year":"2021","journal-title":"Am. Soc. Hematol. Meet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: A multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: A joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Chatzikonstantinou","year":"2020","journal-title":"Leukemia"},{"key":"ref_31","unstructured":"GlaxoSmithKline Inc (2021). Product Monograph: PrSotrovimab for Injection, GlaxoSmithKline Inc."},{"key":"ref_32","unstructured":"Hoffmann-La Roche Limited (2021). Product Monograph: PrCasirivimab and Imdevimab for Injection, Hoffmann-La Roche Limited."},{"key":"ref_33","unstructured":"Eli Lilly Canada Inc. (2020). Product Mongraph: PrBamlanivimab for Injection, Eli Lilly Canada Inc."},{"key":"ref_34","unstructured":"AstraZeneca Canada Inc. (2022). Product Monograph: PrEVUSHELDTM, AstraZeneca Canada Inc."},{"key":"ref_35","unstructured":"(2022, March 04). Fact Sheet for Health Care Providers Emergency Use Authorization (Eua) of Regen-Cov\u00ae (Casirivimab and Imdevimab), Available online: https:\/\/www.fda.gov\/media\/145611\/download."},{"key":"ref_36","unstructured":"(2022, March 04). Fact Sheet for Health Care Providers Emergency Use Authorization (Eua) of Bamlanivimab and Etesevimab, Available online: https:\/\/www.fda.gov\/media\/145802\/download."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV Antibody Combination to Prevent COVID-19","volume":"385","author":"Musser","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jama.2021.8828","article-title":"Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial","volume":"326","author":"Cohen","year":"2021","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1093\/ofid\/ofab466.1646","article-title":"LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab\/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults","volume":"8","author":"Levin","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Levin, M.J., Ustianowski, A., De Wit, S., Launay, O., Avila, M., Templeton, A., Yuan, Y., Seegobin, S., Ellery, A., and Levinson, D.J. (2022). Intramuscular AZD7442 (Tixagevimab\u2013Cilgavimab) for Prevention of Covid-19. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2116620"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"Furman","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus Etesevimab in Mild or Moderate COVID-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"ref_45","unstructured":"(2022, May 03). COVID-19 and CLL: Frequently Asked Questions. Available online: https:\/\/www.hematology.org\/covid-19\/covid-19-and-cll."},{"key":"ref_46","unstructured":"(2022, April 01). Recommendations of the National Comprehensive Cancer Network\u00ae (NCCN\u00ae) Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis. 2022. Version 5.0. Available online: https:\/\/www.nccn.org\/docs\/default-source\/covid-19\/2021_covid-19_vaccination_guidance_v5-0.pdf?sfvrsn=b483da2b_74."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/6\/315\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:22:26Z","timestamp":1760138546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/6\/315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["curroncol29060315"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29060315","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]}}}